Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Eur J Pharmacol ; 633(1-3): 24-32, 2010 May 10.
Artigo em Inglês | MEDLINE | ID: mdl-20153315

RESUMO

Tolerance to brain injury involves hypoxia-inducible factor-1 (HIF-1) and its target genes as the key pathway mediating a cascade of events including cell survival, energetics, and angiogenesis. In this study, we established the treatment paradigms for an in vitro model of tolerance to oxidative injury in primary astrocytic cultures and further examined the roles for the HIF-1 signalling cascade. Isolated murine astrocytes were preconditioned with sub-toxic concentrations of HIF-1 inducers and subsequently exposed to a H(2)O(2) insult, where changes in cell viability and protein expression were determined. Preconditioning with non-damaging concentrations of desferrioxamine (DFO) and ethyl-3,4-dihydroxybenzoate (EDHB) significantly improved cellular viability after H(2)O(2) injury treatment. Time course studies revealed that DFO and EDHB treatments alone induced sequential activation of HIF-1 signal transduction where nuclear HIF-1alpha protein accumulation was detected as early as 2h, followed by downstream upregulation of intracellular and released VEGF from 4h and 8h onwards, respectively. The protective effects of DFO and EDHB preconditioning against H(2)O(2) injury were abolished by co-treatment with cycloheximide, an inhibitor of protein synthesis. Importantly, when the anti-HIF-1 compound, 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1) was used, the cytoprotection and VEGF accumulation produced by DFO and EDHB preconditioning were diminished. These results indicate the essential role of the HIF-1 pathway in our model of tolerance against oxidative injury in cultured astrocytes, and suggest roles for astrocytic HIF-1 expression and VEGF release which may influence the function of surrounding cells and vasculature during oxidative stress-related brain diseases.


Assuntos
Astrócitos/metabolismo , Sobrevivência Celular/efeitos dos fármacos , Inibidores Enzimáticos/farmacologia , Fator 1 Induzível por Hipóxia/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Fator A de Crescimento do Endotélio Vascular/metabolismo , Animais , Células Cultivadas , Cicloeximida/farmacologia , Citoproteção/efeitos dos fármacos , Desferroxamina/antagonistas & inibidores , Desferroxamina/farmacologia , Interações Medicamentosas , Peróxido de Hidrogênio/antagonistas & inibidores , Peróxido de Hidrogênio/toxicidade , Hidroxibenzoatos/antagonistas & inibidores , Hidroxibenzoatos/farmacologia , Indazóis/farmacologia , Camundongos , Transdução de Sinais/efeitos dos fármacos
2.
Rev. Inst. Med. Trop. Säo Paulo ; 47(5): 263-266, Sept.-Oct. 2005.
Artigo em Inglês | LILACS | ID: lil-417084

RESUMO

Os mecanismos utilizados pelo Paracoccidioides brasiliensis para sobreviver em células fagocitárias ainda não estão elucidados. O metabolismo celular férrico é muito importante para o crescimento de inúmeros patógenos intracelulares cuja capacidade de se multiplicarem em fagócitos mononucleares é dependente da disponibilidade intracelular do íon ferro. Assim, o objetivo deste trabalho foi investigar o papel do ferro intracelular sobre a capacidade do P. brasiliensis sobreviver em monócitos humanos. O tratamento de monócitos com deferoxamina, uma droga quelante, diminuiu a sobrevivência de leveduras do fungo de forma dose-dependente. O efeito inibidor da deferoxamina sobre a sobrevivência do P. brasiliensis foi revertido por transferrina saturada com ferro (holotransferrina) mas não por transferrina insaturada (apotransferrina). Estes resultados sugerem que a sobrevivência do P. brasiliensis em monócitos humanos é dependente do íon ferro.


Assuntos
Humanos , Apoproteínas/farmacologia , Desferroxamina/farmacologia , Monócitos/microbiologia , Paracoccidioides/efeitos dos fármacos , Sideróforos/farmacologia , Transferrina/farmacologia , Desferroxamina/antagonistas & inibidores , Ferro/fisiologia , Paracoccidioides/fisiologia , Sideróforos/antagonistas & inibidores
3.
Cell Immunol ; 220(2): 96-106, 2002 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-12657244

RESUMO

Iron is an essential element for the neoplastic cell growth, and iron chelators have been tested for their potential anti-proliferative and cytotoxic effects. To determine the mechanism of cell death induced by iron chelators, we explored the pathways of the three structurally related mitogen-activated protein (MAP) kinase subfamilies during apoptosis induced by iron chelators. We report that the chelator deferoxamine (DFO) strongly activates both p38 MAP kinase and extracellular signal-regulated kinase (ERK) at an early stage of incubation, but slightly activates c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) at a late stage of incubation. Among three MAP kinase blockers used, however, the selective p38 MAP kinase inhibitor SB203580 could only protect HL-60 cells from chelator-induced cell death, indicating that p38 MAP kinase serves as a major mediator of apoptosis induced by iron chelator. DFO also caused release of cytochrome c from mitochondria and induced activation of caspase 3 and caspase 8. Interestingly, treatment of HL-60 cells with SB203580 greatly abolished cytochrome c release, and activation of caspase 3 and caspase 8. Collectively, the current study reveals that p38 MAP kinase plays an important role in iron chelator-mediated cell death of HL-60 cells by activating downstream apoptotic cascade that executes cell death pathway.


Assuntos
Apoptose/fisiologia , Desferroxamina/farmacologia , Quelantes de Ferro/farmacologia , Ferro/metabolismo , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Animais , Apoptose/efeitos dos fármacos , Caspase 3 , Caspase 8 , Caspase 9 , Caspases/metabolismo , Grupo dos Citocromos c/metabolismo , Desferroxamina/antagonistas & inibidores , Ativação Enzimática , Inibidores Enzimáticos/farmacologia , Células HL-60 , Humanos , Imidazóis/farmacologia , Membranas Intracelulares/efeitos dos fármacos , Membranas Intracelulares/fisiologia , Ferro/antagonistas & inibidores , Células Jurkat/enzimologia , Células Jurkat/metabolismo , Potenciais da Membrana/efeitos dos fármacos , Potenciais da Membrana/fisiologia , Camundongos , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/fisiologia , Piridinas/farmacologia , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/fisiologia , Proteínas Quinases p38 Ativadas por Mitógeno
4.
Proc Soc Exp Biol Med ; 152(2): 249-52, 1976 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-935189

RESUMO

The influence of vitamin E on the mobilization and excretion of storage iron induced by DF was studied in normal and iron-overloaded rats. Vitamin E administration in pharmacologic doses resulted in complete inhibition of the effect of DF on storage iron in iron-overloaded rats while no such effect could be demonstrated in rats with normal iron stores. The mechanism of the observed inhibition of DF action by vitamin E is at present unknown. Nevertheless this drug interaction has to be considered in view of ongoing therapeutic trials where both antioxidants and iron chelating drugs are administered simultaneously to thalassemic patients with transfusion induced iron overload.


Assuntos
Desferroxamina/farmacologia , Ferro/metabolismo , Vitamina E/farmacologia , Animais , Desferroxamina/antagonistas & inibidores , Desferroxamina/uso terapêutico , Feminino , Ferritinas/metabolismo , Ferro/sangue , Ferro/urina , Fígado/metabolismo , Ratos , Baço/metabolismo , Talassemia/terapia , Vitamina E/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA